Browsing by Subject
Ara mostrant els elements 21-40 d 90
-
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
(American Society of Clinical Oncology, 2022-10-10) -
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
(The American Society of Hematology, 2022-08-25) -
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
(American Association for Cancer Research, 2023-01-04) -
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
(American Society of Clinical Oncology, 2023-05-01) -
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
(American Society of Clinical Oncology, 2022-10-01) -
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
(American Society of Hematology, 2023-01-12) -
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
(Springer Nature, 2020-12-08) -
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
(Future Science Group, 2021-08)